Showing results (41-50 of 289) with videos related to
Sort By:
Pageof 29
British Journal of Haematology|June 1, 1997
Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection processF Bertoni, G Cazzaniga, G Bosshard, et al.British Journal of Cancer|February 4, 2010
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trialM Joerger, A D R Huitema, S Krähenbühl, et al.Leukemia & Lymphoma|January 24, 2004
Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patientsG Martinelli, E Cocorocchio, P C Saletti, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 27, 2005
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomasK Lacrima, A Valentini, C Lambertini, et al.Leukemia & Lymphoma|June 14, 2003
ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphomaG Martinelli, P F Ferrucci, W Mingrone, et al.Leukemia & Lymphoma|August 1, 1997
Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphomaG Pinotti, E Zucca, E Roggero, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1991
Altered gene expression and oncogenesis of B-cell neoplasiaF E Cotter, E ZuccaAnnals of Oncology : Official Journal of the European Society for Medical Oncology|September 3, 2010
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)A Conconi, G Martinelli, A Lopez-Guillermo, et al.Schweizerische Medizinische Wochenschrift|July 8, 1980
[Results of a pilot study with high-dose medroxyprogesterone acetate in the treatment of metastasizing breast carcinoma]M Castiglione, F CavalliCurrent Medicinal Chemistry|June 10, 2011
Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural modelsE Crespan, E Zucca, G MagaPageof 29